| 证券代码 | FTSV.O |
| 证券名称 | Forty Seven Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-06-28 |
| 首发价格(元) | 16 USD |
| 首发数量(股) | 7035000 |
| 首发募资额(元) | 112,560,000.00 USD |
| 首发主承销商 | Morgan Stanley & Co. LLC,Credit Suisse Securities (USA) LLC |
| 货币单位 | USD |
| 公司名称 | Forty Seven, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 1490 O’Brien Drive, Suite A, Menlo Park, California, USA |
| 成立日期 | 2014 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.fortyseveninc.com |
| 电话 | +1 (650) 352-4150 |
| 传真 | - |
| 公司简介 | Forty Seven, Inc. is a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. It founded Forty Seven based on the insight that blocking CD47, a key signaling molecule that is overexpressed on cancer cells, renders tumors susceptible to macrophages. By harnessing macrophages, it believes that its lead product candidate, 5F9, dosed as a monotherapy or in combination with marketed cancer therapies, can transform the treatment of cancer. |